Year archive

Sanofi — 2011 filings

All 300 regulatory filings released by Sanofi (SAN) in 2011, sourced directly from the official regulator.

300 Filings

2011 Period

2011 filings (300)

Filing	Released	Lang
FORM 6-K Foreign Filer Report	2011-12-22	English
Genzyme annonce les premiers résultats de l’étude TENERE évaluant le tériflunomide par voie orale dans la sclérose en plaques de type récurrente Earnings Release Q4 2011	2011-12-20	French
Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis Earnings Release Q4 2011	2011-12-20	English
Sanofi Completes Divestiture of Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. M&A Activity	2011-12-19	English
Sanofi annonce la clôture de la cession de sa Division Dermatologie Dermik à Valeant Pharmaceuticals International, Inc. M&A Activity	2011-12-19	French
FORM 15 Regulatory Filings	2011-12-16	English
Sanofi présente au Congrès Mondial du Diabète les résultats d’une nouvelle méta-analyse confirmant la sécurité d’emploi de Lantus® Earnings Release FY 2011	2011-12-07	French
Sanofi reports results of new meta-analysis reinforcing Lantus® safety profile at the World Diabetes Congress Regulatory Filings	2011-12-07	English
Sanofi Reports Positive Results for Once-daily Lyxumia® (lixisenatide) in Combination with Lantus® (insulin glargine) in Type 2 Diabetes Regulatory Filings	2011-12-06	English
Sanofi annonce des résultats positifs pour Lyxumia® (lixisénatide) en une injection quotidienne en association avec Lantus® (insuline glargine) dans le diabète de type 2 Earnings Release Q4 2011	2011-12-06	French
Sanofi Confirms its Decades-Long Commitment to the Fight against Malaria Environmental & Social Information	2011-11-29	English
Sanofi confirme son engagement depuis des décennies dans la lutte contre le Paludisme Regulatory Filings	2011-11-29	French
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Regulatory Filings	2011-11-21	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Regulatory Filings	2011-11-21	English
FORM 6-K Foreign Filer Report	2011-11-17	English
FORM 6-K Foreign Filer Report	2011-11-14	English
Genzyme annonce les résultats positifs d’une étude de Phase 3 avec Alemtuzumab (LEMTRADA *) dans la sclérose en plaques Regulatory Filings	2011-11-14	French
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA*) in Multiple Sclerosis Regulatory Filings	2011-11-14	English
Sanofi et Regeneron annoncent des résultats préliminaires positifs de Phase II dans l’hypercholestérolémie pour un anticorps anti-PCSK9 Earnings Release Q4 2011	2011-11-10	French
Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia Earnings Release Q4 2011	2011-11-10	English
FORM 6-K Foreign Filer Report	2011-11-03	English
Chiffre d’affaires en hausse de 10,1% et résultat net des activités en hausse de 4,1 % à changes constants Interim / Quarterly Report 9M 2011	2011-11-03	French
Net sales up 10.1% and Business net income up 4.1% at CER Earnings Release 9M 2011	2011-11-03	English
FORM 6-K Foreign Filer Report	2011-10-25	English
Sanofi nomme David Meeker Directeur Général de Genzyme Board/Management Information	2011-10-24	French
Sanofi appoints David Meeker, Chief Executive Officer of Genzyme Board/Management Information	2011-10-24	English
Alemtuzumab (Lemtrada™) réduit significativement les rechutes dans la sclérose en plaques comparé à l’interféron Bêta-1a dans une étude de Phase III Regulatory Filings	2011-10-22	French
Alemtuzumab (Lemtrada™) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study Legal Proceedings Report	2011-10-22	English
Le médicament oral tériflunomide (Aubagio™(*)) réduit significativement les rechutes entraînant une hospitalisation chez les patients atteints de sclérose en plaques Earnings Release Q4 2011	2011-10-20	French
Oral Therapy Teriflunomide (Aubagio™(*)) Significantly Reduces Relapses Leading to Hospitalization of Patients with Multiple Sclerosis Regulatory Filings	2011-10-20	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-10-19	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Regulatory Filings	2011-10-19	English
Sanofi et sa filiale Genzyme présenteront plus de 20 communications scientifiques au Congrès de l’ECTRIMS/ACTRIMS Report Publication Announcement	2011-10-18	French
Sanofi and its subsidiary Genzyme to Feature More than 20 Data Presentations at the ECTRIMS/ACTRIMS Congress Earnings Release Q4 2011	2011-10-18	English
Le médicament expérimental oral Teriflunomide (Aubagio™(*)) dans la sclérose en plaques réduit significativement les rechutes, la progression du handicap et l’activité de la maladie Earnings Release Q4 2011	2011-10-05	French
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity Earnings Release Q4 2011	2011-10-05	English
FORM 6-K Foreign Filer Report	2011-10-03	English
FORM 6-K Foreign Filer Report	2011-09-29	English
FORM 6-K Foreign Filer Report	2011-09-29	English
FORM 424(B)(5) Prospectus	2011-09-28	English
FORM 6-K Foreign Filer Report	2011-09-28	English
Sanofi place un emprunt obligataire de 1 milliard de dollars US Capital/Financing Update	2011-09-28	French
Sanofi successfully prices USD 1 billion bond issue Capital/Financing Update	2011-09-28	English
FWP Regulatory Filings	2011-09-27	English
FORM 424(B)(5) (PRELIMINARY) Prospectus	2011-09-27	English
FORM 6-K Foreign Filer Report	2011-09-27	English
Regulatory Filings 2011 Regulatory Filings	2011-09-22	English
L’Agence européenne du médicament (EMA) confirme le bénéfice-risque positif de Multaq® Regulatory Filings	2011-09-22	French
European Medicines Agency (EMA) confirms positive benefit-risk balance for Multaq® Regulatory Filings	2011-09-22	English
Sanofi Pasteur acquiert l’exclusivité mondiale des droits pour un vaccin et un traitement contre l’acné Regulatory Filings	2011-09-21	French
Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and Treatment Regulatory Filings	2011-09-21	English
Sanofi Pasteur fait don à l’OMS d’une souche vaccinale utilisée pour l’éradication de la polio Regulatory Filings	2011-09-20	French
Sanofi Pasteur Donates Vaccine Strain Used for Polio Eradication to WHO Regulatory Filings	2011-09-20	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-09-20	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Regulatory Filings	2011-09-20	English
FORM 6-K Foreign Filer Report	2011-09-19	English
La justice américaine se prononce en faveur de Sanofi US dans le litige Eloxatine® Legal Proceedings Report	2011-09-19	French
U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation Legal Proceedings Report	2011-09-19	English
Regulatory Filings 2011 Regulatory Filings	2011-09-12	English
Initiation of Lantus leads to better glycemic control at similar weight gain versus other comparators in patients with Type 2 Diabetes Regulatory Filings	2011-09-12	English
L’instauration de Lantus chez des patients diabétiques de type 2 permet d’obtenir un meilleur contrôle de la glycémie avec une prise de poids similaire à celle des autres traitements Regulatory Filings	2011-09-12	French
Lyxumia® (lixisénatide) aussi efficace pour améliorer le contrôle de la glycémie dans le diabète de type 2 avec une dose unique ou avec deux doses à l’instauration du traitement Earnings Release Q3 2011	2011-09-12	French
Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes Earnings Release Q3 2011	2011-09-12	English
FORM 6-K Foreign Filer Report	2011-09-09	English
Sanofi Announces New Long Term Objectives Investor Presentation	2011-09-06	English
Sanofi annonce de nouveaux objectifs à long terme Investor Presentation	2011-09-06	French
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-08-31	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Regulatory Filings	2011-08-31	English
Regulatory Filings 2011 Regulatory Filings	2011-08-26	English
Mise en ligne du rapport financier semestriel 2011 Report Publication Announcement	2011-07-29	French
Availability Online of the Group’s Half-Year Financial Report for 2011 Report Publication Announcement	2011-07-29	English
Rapport Financier Semestriel 2011 Interim / Quarterly Report H1 2011	2011-07-29	French
FORM 6-K Foreign Filer Report	2011-07-29	English
FORM 6-K Foreign Filer Report	2011-07-28	English
Le Dr. David-Alexandre Gros nommé Chief Strategy Officer de Sanofi Board/Management Information	2011-07-28	French
Dr. David-Alexandre Gros appointed Chief Strategy Officer of Sanofi Board/Management Information	2011-07-28	English
Sales growth of 6.9% thanks to Genzyme acquisition and performance of growth platforms - Positive impact from Genzyme on business EPS Earnings Release Q2 2011	2011-07-28	English
Progression du chiffre d’affaires de 6,9% grâce à l’acquisition de Genzyme et à la performance des plateformes de croissance - Contribution positive de Genzyme au BNPA des activités Earnings Release Q2 2011	2011-07-28	French
Mise à jour sur l’approvisionnement des Produits de Genzyme Earnings Release Q2 2011	2011-07-28	French
Genzyme Product Supply Update Regulatory Filings	2011-07-28	English
Regulatory Filings 2011 Regulatory Filings	2011-07-27	English
New Senior Executives appointed at Sanofi: Greg Irace, Senior Vice President, Global Services - Anne Whitaker, President, North America, Pharmaceuticals Board/Management Information	2011-07-22	English
Nouvelles Nominations à la Direction de Sanofi : Greg Irace, Senior Vice-Président, Services Globaux - Anne Whitaker, Président, Amérique du Nord, Pharmacie Board/Management Information	2011-07-22	French
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Notice of Dividend Amount	2011-07-21	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-07-21	English
Sanofi et Regeneron annoncent des résultats positifs de Phase 2b pour sarilumab dans la polyarthrite rhumatoïde Regulatory Filings	2011-07-12	French
Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis Regulatory Filings	2011-07-12	English
FORM 6-K Foreign Filer Report	2011-07-11	English
Sanofi cède sa Division Dermatologie Dermik à Valeant Pharmaceuticals International, Inc. M&A Activity	2011-07-11	French
Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc. M&A Activity	2011-07-11	English
Sanofi annonce les premiers résultats positifs de la première étude de phase 3 sur Alemtuzumab (Lemtrada™(*)) dans la Sclérose en Plaques Earnings Release Q3 2011	2011-07-11	French
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™ (*)) in Multiple Sclerosis Regulatory Filings	2011-07-11	English
Sanofi fait le point sur l’essai de phase IIIb PALLAS consacré à Multaq® Earnings Release Q3 2011	2011-07-07	French
Sanofi Provides Multaq® Phase IIIb PALLAS Trial Update Regulatory Filings	2011-07-07	English
FORM 6-K Foreign Filer Report	2011-07-06	English
Sanofi and Rib-X Pharmaceuticals Sign a Research Collaboration Agreement on Novel Classes of Antibiotics Regulatory Filings	2011-07-06	English
Sanofi et Rib-X Pharmaceuticals signent un accord de Recherche sur de nouvelles classes d’antibiotiques Regulatory Filings	2011-07-06	French
Regulatory Filings 2011 Regulatory Filings	2011-07-05	English
Sanofi conclut une collaboration de recherche avec le Weill Cornell Medical College pour développer de nouveaux traitements antituberculeux Regulatory Filings	2011-06-29	French
Sanofi Enters Into Research Collaboration with Weill Cornell Medical College to Discover New Treatments for Tuberculosis Regulatory Filings	2011-06-29	English
Regulatory Filings 2011 Regulatory Filings	2011-06-28	English
Présentation de données sur mipomersen au Congrès de l’European Atherosclerosis Society Regulatory Filings	2011-06-28	French
Mipomersen Data Presented at European Atherosclerosis Society Congress Regulatory Filings	2011-06-28	English
11-K Regulatory Filings	2011-06-27	English
11 K Regulatory Filings	2011-06-27	English
Sanofi nomme Peter Guenter, Senior Vice-Président, Europe Board/Management Information	2011-06-27	French
Sanofi appoints Peter Guenter, Senior Vice President, Europe Board/Management Information	2011-06-27	English
Sanofi Announces Positive Results from the “All to Target” Study Evaluating Two Lantus® and Apidra® Regimens versus Premixed Regimen Regulatory Filings	2011-06-24	English
Sanofi annonce des résultats positifs de l’étude « All to Target » comparant deux traitements par Lantus® et Apidra® à un traitement par insuline premix Regulatory Filings	2011-06-24	French
Présentation de résultats positifs sur l’agent expérimental Lyxumia® (lixisénatide) aux 71e Séances scientifiques annuelles de l’American Diabetes Association Earnings Release Q2 2011	2011-06-24	French
Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Association’s 71st Annual Scientific Sessions Earnings Release Q2 2011	2011-06-24	English
11-K Regulatory Filings	2011-06-24	English
Typhim Vi®, le vaccin de Sanofi Pasteur contre la fièvre typhoïde, préqualifié par l’Organisation Mondiale de la Santé Regulatory Filings	2011-06-23	French
Sanofi Pasteur’s Typhoid Vaccine, Typhim Vi®, Granted Prequalification by the World Health Organization Regulatory Filings	2011-06-23	English
Sanofi conclut un accord global avec Medco et UBC pour améliorer la qualité des soins des patients grâce à l’utilisation de données de vie réelle Regulatory Filings	2011-06-22	French
Sanofi Establishes a Global Agreement with Medco and UBC to Improve Quality of Patient Care through Real-World Evidence Regulatory Filings	2011-06-22	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Regulatory Filings	2011-06-20	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-06-20	English
FORM 6-K Foreign Filer Report	2011-06-20	English
Sanofi noue une collaboration de recherche avec la société de biotechnologies Audion Therapeutics pour le développement de traitements potentiels de la déficience auditive Regulatory Filings	2011-06-16	French
Sanofi Enters into Research Collaboration with Biopharmaceutical Company Audion Therapeutics to Develop Potential Treatments for Hearing Loss Regulatory Filings	2011-06-16	English
Sanofi annonce que 58% du dividende 2010 sera payé en actions et 42% en numéraire Notice of Dividend Amount	2011-06-15	French
Sanofi announces that 58% of the 2010 dividend will be paid in shares and 42% in cash Notice of Dividend Amount	2011-06-15	English
New Data in Breast and Ovarian Cancer Presented at ASCO Support Continued Development of Iniparib Regulatory Filings	2011-06-06	English
De nouvelles données dans le cancer du sein et de l’ovaire présentées à l’ASCO valident la poursuite du développement d’iniparib Legal Proceedings Report	2011-06-06	French
ZALTRAP™ (aflibercept) améliore significativement la survie des patients atteints d’un cancer colorectal métastatique ayant déjà été traités Regulatory Filings	2011-06-06	French
ZALTRAP™ (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients Earnings Release Q1 2011	2011-06-06	English
La sémuloparine de Sanofi étudiée chez les patients cancéreux à l’instauration des chimiothérapies montre une réduction de 64 % du risque de thrombose veineuse potentiellement fatale Legal Proceedings Report	2011-06-04	French
Sanofi's Investigational Semuloparin in Cancer Patients initiating Chemotherapy Shows a 64 % Risk Reduction in Life-Threatening Venous Thrombo-Embolism Regulatory Filings	2011-06-04	English
Résultats positifs significatifs en phase III pour Lyxumia®, en complément à une insuline basale, dans le programme GetGoal de Sanofi Earnings Release Q2 2011	2011-05-31	French
Sanofi GetGoal Program on Lyxumia®, as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results Earnings Release Q2 2011	2011-05-31	English
Sanofi et DNDi - Drugs for Neglected Diseases initiative - signent un accord innovant pour la recherche de nouveaux médicaments contre les maladies tropicales négligées Regulatory Filings	2011-05-30	French
Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement to Generate New Drugs for Neglected Tropical Diseases Regulatory Filings	2011-05-30	English
POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 Regulatory Filings	2011-05-24	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Notice of Dividend Amount	2011-05-19	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-05-19	English
Les données présentées au Congrès de l’ASCO soulignent l’Engagement de Sanofi pour la Recherche et l’Identification de traitements pour les patients cancéreux Regulatory Filings	2011-05-19	French
Data at ASCO Showcase Sanofi’s Commitment to Research and Identify Treatments for Cancer Patients Regulatory Filings	2011-05-19	English
FORM 6-K Foreign Filer Report	2011-05-16	English
Sanofi et Glenmark Pharmaceuticals signent un accord de licence sur un nouvel anticorps monoclonal pour la Maladie de Crohn et d’autres maladies auto-immunes chroniques Capital/Financing Update	2011-05-16	French
Sanofi and Glenmark Pharmaceuticals Sign License Agreement on Novel Monoclonal Antibody for Crohn’s Disease and Other Chronic Autoimmune Disorders M&A Activity	2011-05-16	English
Sanofi Pasteur lance Pentaxim® en Chine le premier vaccin combiné 5-en-1 Regulatory Filings	2011-05-11	French
Sanofi Pasteur Launches Pentaxim®, First 5-in-1 Combination Vaccine in China Regulatory Filings	2011-05-11	English
Sanofi soutient le lancement du programme « China Initiative for Diabetes Excellence» Regulatory Filings	2011-05-11	French
Sanofi Supports Launch of the “China Initiative for Diabetes Excellence” Regulatory Filings	2011-05-11	English
Homologation par la FDA américaine du nouveau vaccin grippe administré par microinjection intradermique de Sanofi Pasteur Earnings Release Q2 2011	2011-05-10	French
FDA Licenses Sanofi Pasteur’s New Influenza Vaccine Delivered by Intradermal Microinjection Regulatory Filings	2011-05-10	English
FORM 6-K Foreign Filer Report	2011-05-09	English
Prospectus 2011 Prospectus	2011-05-09	English
Assemblée Générale Mixte du 6 mai 2011 Notice of Dividend Amount	2011-05-06	French
Combined General Shareholder Meeting of May 6, 2011 AGM Information	2011-05-06	English
Sanofi-aventis and Medicines for Malaria Venture Join Forces to Develop Innovative Malaria Drugs Regulatory Filings	2011-05-05	English
Sanofi-aventis et Medicines for Malaria Venture s’associent pour développer des antipaludiques innovants Regulatory Filings	2011-05-05	French
AVENANT AU CONTRAT DE LIQUIDITE AVEC EXANE BNP PARIBAS Transaction in Own Shares	2011-05-03	French
AMENDMENT TO THE LIQUIDITY CONTRACT WITH EXANE BNP PARIBAS Capital/Financing Update	2011-05-03	English
Regulatory Filings 2011 Regulatory Filings	2011-04-29	English
FORM 6-K Foreign Filer Report	2011-04-28	English
Forte performance des plateformes de croissance au premier trimestre 2011 Earnings Release Q1 2011	2011-04-28	French
Strong performance of growth platforms in Q1 2011 Earnings Release Q1 2011	2011-04-28	English
Sanofi-aventis et Regeneron publient des résultats positifs de Phase III sur ZALTRAP® (aflibercept) dans le traitement de deuxième ligne du cancer colorectal métastatique Earnings Release Q2 2011	2011-04-26	French
Sanofi-aventis and Regeneron Report Positive Phase III Results with ZALTRAP® (aflibercept) in Second-line Metastatic Colorectal Cancer Earnings Release Q2 2011	2011-04-26	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Notice of Dividend Amount	2011-04-26	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-04-26	English
FORM 6-K Foreign Filer Report	2011-04-20	English
Des données de Phase II à cinq ans sur alemtuzumab dans la sclérose en plaques montrent un arrêt de la progression de la maladie chez un large pourcentage de patients Legal Proceedings Report	2011-04-14	French
Five-year Alemtuzumab Phase 2 Data Shows Large Percentage of MS Patients Remain Free of Clinically-Active Disease Regulatory Filings	2011-04-14	English
SCHEDULE 13D Major Shareholding Notification	2011-04-13	English
Lixisénatide réduit significativement le taux d’HbA1c sans augmenter le risque d’hypoglycémie chez les patients non contrôlés par sulfamides hypoglycémiants Earnings Release Q2 2011	2011-04-12	French
Lixisenatide Significantly Reduces HbA1c Without Increasing Hypoglycemia in Patients Uncontrolled on Sulfonylureas Earnings Release Q2 2011	2011-04-12	English
FORM 4 Director's Dealing	2011-04-08	English
Sanofi-aventis réalise l’acquisition de Genzyme Corporation M&A Activity	2011-04-08	French
Sanofi-Aventis Completes Acquisition of Genzyme Corporation M&A Activity	2011-04-08	English
SC TO-T/A Filing Regulatory Filings	2011-04-08	English
425 Filing Regulatory Filings	2011-04-08	English
Genzyme présente des résultats de Phase II d’alemtuzumab dans la sclérose en plaques au 63e Congrès annuel de l’American Academy Of Neurology Regulatory Filings	2011-04-07	French
Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy of Neurology Legal Proceedings Report	2011-04-07	English
FORM 3 Director's Dealing	2011-04-06	English
Présentation à l’ACC des données de deux études de Phase III sur mipomersen Regulatory Filings	2011-04-05	French
Data from Two Mipomersen Phase 3 Trials Presented at ACC Earnings Release FY 2010	2011-04-05	English
AUTO-GENERATED PAPER DOCUMENT Regulatory Filings	2011-04-04	English
Sanofi-aventis clôture avec succès son offre publique d'échange sur Genzyme Corporation M&A Activity	2011-04-04	French
Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation M&A Activity	2011-04-04	English
SC TO-T/A Filing Regulatory Filings	2011-04-04	English
425 Filing Regulatory Filings	2011-04-04	English
SC TO-T/A Filing Regulatory Filings	2011-03-31	English
FORM 6-K Foreign Filer Report	2011-03-30	English
424B3 Prospectus	2011-03-30	English
Sanofi-aventis : Document d’information annuel Regulatory Filings FY 2010	2011-03-30	French
Regulatory Filings 2011 Regulatory Filings	2011-03-30	English
Sanofi-aventis annonce l’obtention du visa de la SEC sur le document d’enregistrement des CVR émis dans le cadre de l’acquisition de Genzyme M&A Activity	2011-03-29	French
Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective M&A Activity	2011-03-29	English
Regulatory Filings 2011 Regulatory Filings	2011-03-29	English
SC TO-T/A Filing Regulatory Filings	2011-03-29	English
425 Filing Regulatory Filings	2011-03-29	English
FORM 8-A Regulatory Filings	2011-03-28	English
Regulatory Filings 2011 Regulatory Filings	2011-03-28	English
AMENDMENT NO. 3 TO FORM F-4 Regulatory Filings	2011-03-28	English
FORM 6-K Foreign Filer Report	2011-03-28	English
424(B)(5) Prospectus	2011-03-24	English
AMENDMENT NO. 2 TO FORM F-4 Regulatory Filings	2011-03-24	English
SC TO-T/A Filing Regulatory Filings	2011-03-24	English
FORM 6-K Foreign Filer Report	2011-03-23	English
Sanofi-aventis renforce son engagement en ophtalmologie par un partenariat avec l’Institut de la Vision M&A Activity	2011-03-23	French
Sanofi-aventis Strengthens Commitment to Ophthalmology through Partnership with The Vision Institute Regulatory Filings	2011-03-23	English
FWP Regulatory Filings	2011-03-23	English
FWP Regulatory Filings	2011-03-23	English
Sanofi-aventis place un emprunt obligataire de 7 milliards de dollars US Capital/Financing Update	2011-03-23	French
Sanofi-aventis successfully prices USD 7 billion bond issue Capital/Financing Update	2011-03-23	English
425 Filing Regulatory Filings	2011-03-23	English
SC TO-T/A Filing Regulatory Filings	2011-03-23	English
Merial - Santé Animale M&A Activity	2011-03-22	French
Merial - Animal Health Regulatory Filings	2011-03-22	English
FORM 424(B)(5) Prospectus	2011-03-22	English
FORM 6-K Foreign Filer Report	2011-03-22	English
Merck et sanofi-aventis maintiennent leurs activités séparées dans la santé animale Regulatory Filings	2011-03-22	French
Merck and sanofi-aventis to maintain separate businesses in animal health M&A Activity	2011-03-22	English
JEVTANA® (cabazitaxel) approuvé par la Commission européenne pour le traitement en 2ème ligne du cancer avancé de la prostate Legal Proceedings Report	2011-03-20	French
JEVTANA® (cabazitaxel) Approved by European Commission for Treatment of Advanced Second-line Prostate Cancer Legal Proceedings Report	2011-03-20	English
AMENDMENT NO. 1 TO FORM F-4 Regulatory Filings	2011-03-18	English
Regulatory Filings 2011 Regulatory Filings	2011-03-18	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-03-18	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-03-18	English
Sanofi-aventis et ses collaborateurs contribuent au Fonds de secours des victimes du séisme du Tohoku Regulatory Filings	2011-03-18	French
Sanofi-aventis and its employees Donate to Tohoku Pacific Earthquake Relief Fun Regulatory Filings	2011-03-18	English
SC TO-T/A Filing Regulatory Filings	2011-03-18	English
FORM 6-K Foreign Filer Report	2011-03-16	English
Regulatory Filings 2011 Regulatory Filings	2011-03-11	English
Sanofi-aventis appoints Dr. Richard Klausner as Chairman of the Strategic Development and Scientific Advisory Council Board/Management Information	2011-03-11	English
Sanofi-aventis nomme le Dr. Richard Klausner à la Présidence du Comité de Développement Stratégique et de Conseil Scientifique Board/Management Information	2011-03-11	French
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer Regulatory Filings	2011-03-10	English
Sanofi-aventis et Regeneron annoncent les premiers résultats d’une étude de Phase III sur Aflibercept (VEGF Trap) dans le traitement de deuxième ligne du cancer du poumon non à petites cellules Legal Proceedings Report	2011-03-10	French
Regulatory Filings 2011 Regulatory Filings	2011-03-10	English
Composition du Conseil d’Administration de sanofi-aventis Board/Management Information	2011-03-09	French
Composition of the Board of Directors of sanofi-aventis Board/Management Information	2011-03-09	English
Sanofi-aventis signs New Agreement with the World Health Organization (WHO) to fight Neglected Tropical Diseases Regulatory Filings	2011-03-08	English
Sanofi-aventis signe un nouvel accord avec l'Organisation Mondiale de la Santé (OMS) pour lutter contre les maladies tropicales négligées Regulatory Filings	2011-03-08	French
FORM F-4 Regulatory Filings	2011-03-07	English
Sanofi-aventis Extends Offer for all Outstanding Shares of Genzyme M&A Activity	2011-03-07	English
Sanofi-aventis prolonge l’offre visant l’intégralité des actions en circulation de Genzyme M&A Activity	2011-03-07	French
SC TO-T/A Filing Regulatory Filings	2011-03-07	English
425 Filing Regulatory Filings	2011-03-07	English
Dépôt du Document de Référence 2010, contenant le Rapport Financier Annuel et du « Form 20-F » américain Report Publication Announcement	2011-03-01	French
Filing of the 2010 U.S. Form 20-F and French “Document de Référence” containing the Annual Financial Report Report Publication Announcement FY 2010	2011-03-01	English
FORM 20-F Annual Report FY 2010	2011-03-01	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-02-25	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-02-25	English
Sanofi-aventis annonce l’approbation et la clôture du rachat de BMP Sunstone Corporation créant une plateforme solide de Santé Grand Public en Chine Delisting Announcement	2011-02-24	French
Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China Delisting Announcement	2011-02-24	English
Sanofi Pasteur et l’International Vaccine Institute s’allient contre la dengue Regulatory Filings	2011-02-21	French
Sanofi Pasteur and International Vaccine Institute Partner against Dengue Regulatory Filings	2011-02-21	English
SC TO-T/A Filing Regulatory Filings	2011-02-18	English
425 Filing Regulatory Filings	2011-02-18	English
425 Filing Regulatory Filings	2011-02-17	English
SC TO-T/A Filing Regulatory Filings	2011-02-17	English
Sanofi-aventis va acquérir Genzyme pour 74,00 USD en numéraire par action plus un Contingent Value Right (Certificat de Valeur Conditionnelle) M&A Activity	2011-02-16	French
Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right M&A Activity	2011-02-16	English
425 Filing Regulatory Filings	2011-02-16	English
425 Filing Regulatory Filings	2011-02-16	English
SC TO-T/A Filing Regulatory Filings	2011-02-16	English
425 Filing Regulatory Filings	2011-02-16	English
SC TO-T/A Filing Regulatory Filings	2011-02-16	English
Regulatory Filings 2011 Regulatory Filings	2011-02-14	English
FORM 6-K Foreign Filer Report	2011-02-09	English
Résultats solides en 2010 Earnings Release FY 2010	2011-02-09	French
Solid results in 2010 Earnings Release Q4 2010	2011-02-09	English
SC TO-T/A Filing Regulatory Filings	2011-02-09	English
Regulatory Filings 2011 Regulatory Filings	2011-02-03	English
Sanofi-aventis annonce des résultats initiaux positifs de Phase III pour lixisénatide Regulatory Filings	2011-02-02	French
Sanofi-aventis Announces Positive Top-line Lixisenatide Phase III Results Earnings Release Q1 2011	2011-02-02	English
SC TO-T/A Filing Regulatory Filings	2011-01-31	English
FORM 6-K Foreign Filer Report	2011-01-28	English
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financier Share Issue/Capital Change	2011-01-28	French
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g Declaration of Voting Results & Voting Rights Announcements	2011-01-28	English
Sanofi-aventis annonce les premiers résultats de l’étude de Phase III sur BSI-201 dans le cancer du sein métastatique triple négatif Regulatory Filings	2011-01-27	French
Sanofi-aventis Reports Top-line Results from Phase III Study with BSI-201 in Metastatic Triple-Negative Breast Cancer Earnings Release Q1 2011	2011-01-27	English
U.S. FDA Approves Number One U.S.-Prescribed Allergy Treatment Allegra® for Over-The-Counter Use Regulatory Filings	2011-01-25	English
La FDA autorise Allegra®, premier traitement contre les allergies aux Etats-Unis, à la vente sans ordonnance Regulatory Filings	2011-01-25	French
Bristol-Myers Squibb et sanofi-aventis annoncent que la FDA a décidé d’accorder le statut d’exclusivité pédiatrique à PLAVIX® Regulatory Filings	2011-01-25	French
Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX® Regulatory Filings	2011-01-25	English
Sanofi-aventis Extends Tender Offer for All Outstanding Shares of Genzyme M&A Activity	2011-01-24	English
Sanofi-aventis prolonge l’offre publique d’achat visant l’intégralité des actions en circulation de Genzyme M&A Activity	2011-01-24	French
SC TO-T/A Filing Regulatory Filings	2011-01-24	English
JEVTANA® (cabacitaxel) recommandé pour approbation dans l’Union Européenne dans le cancer de la prostate Legal Proceedings Report	2011-01-21	French
JEVTANA® (cabazitaxel) for Prostate Cancer Recommended for Approval in the European Union Regulatory Filings	2011-01-21	English
Regulatory Filings 2011 Regulatory Filings	2011-01-20	English
FORM 6-K Foreign Filer Report	2011-01-14	English
European Commission Clears Acquisition of Genzyme Corporation by sanofi-aventis M&A Activity	2011-01-12	English
La Commission Européenne autorise l’acquisition de Genzyme Corporation par sanofi-aventis M&A Activity	2011-01-12	French
Sanofi-aventis Enters into Two Research & Development Collaborations with the University of California, San Francisco Regulatory Filings	2011-01-12	English
Sanofi-aventis noue deux collaborations de Recherche et Développement avec l’Université de Californie à San Francisco Regulatory Filings	2011-01-12	French
SC TO-T/A Filing Regulatory Filings	2011-01-12	English
SC TO-T/A Filing Regulatory Filings	2011-01-11	English
SC TO-T/A Filing Regulatory Filings	2011-01-10	English
Déclaration sur les discussions avec Genzyme M&A Activity	2011-01-09	French
Statement on Genzyme discussions M&A Activity	2011-01-09	English
Regulatory Filings 2011 Regulatory Filings	2011-01-07	English
Sanofi-aventis nomme de Nouveaux Dirigeants dans les Marchés Emergents Board/Management Information	2011-01-07	French
Sanofi-aventis appoints New Senior Managers in Emerging Markets Board/Management Information	2011-01-07	English
Publication dans The New England Journal of Medicine des données positives de phase II sur BSI-201 (iniparib) dans le traitement du cancer du sein métastatique triple négatif Earnings Release Q1 2011	2011-01-05	French
Positive Phase II Results with BSI-201 (Iniparib) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine Earnings Release Q1 2011	2011-01-05	English

Filings by year

2026 123 filings
2025 367 filings
2024 220 filings
2023 220 filings
2022 253 filings
2021 243 filings
2020 234 filings
2019 261 filings
2018 221 filings
2017 245 filings
2016 270 filings
2015 188 filings
2014 229 filings
2013 229 filings
2012 210 filings
2011 300 filings
2010 256 filings
2009 270 filings
2008 53 filings
2004 6 filings
2003 1 filing
2002 1 filing
2000 1 filing